why choose us

Clinical Trials Search

Showing 2,840 of 131,434 result(s)
Food-effect Study of Ecopipam Pharmacokinetics

Status: COMPLETED

Condition: Food-effect

Interventions: A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)

Date: 2024-10-30

Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

Status: COMPLETED

Condition: Healthy Participants

Interventions: GP681 tablet, 20 mg, single oral dose in each Group.

Date: 2024-10-30

Patient Reported Outcomes With WaveLight LASIK

Status: COMPLETED

Condition: Myopia

Interventions: Phorcidies Planned Contoura LASIK

Date: 2024-10-30

Trial of an Inactivated Chikungunya Virus Vaccine

Status: COMPLETED

Condition: Chikungunya Fever

Interventions: HydroVax-005 CHIKV vaccine

Date: 2024-10-30

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Status: COMPLETED

Condition: Respiratory Viral Infections

Interventions: Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing.
MxA measurements on Days 4, 7, and 10 will be performed only for p

Date: 2024-10-30

Effectiveness Study of an Exercise Program for Older Adults With Chronic Musculoskeletal Pain

Status: COMPLETED

Condition: Chronic Musculoskeletal Pain

Interventions: The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric e

Date: 2024-10-30

Efficacy of Botulinum Toxin and Marjoram Oil Applications in Bruxism

Status: COMPLETED

Condition: Bruxism, Sleep

Interventions: Treatment for bruxism

Date: 2024-10-30

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus

Status: COMPLETED

Condition: Healthy Participants

Interventions: Single dose of AZD5004 oral on Day1

Date: 2024-10-29

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ?55 Years of Age

Status: COMPLETED

Condition: Pharmacokinetics

Interventions: Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours

Date: 2024-10-29